Læknablaðið - 15.10.2012, Page 33

Y F I R L I T
Heimildir
1. Jóhannesson Þ, Kristinsson J, Snædal J. Hrömunarsjúk-
dómar í heila - oxavamarensím og kopar. Kynning á
rannsóknum. Læknablaðið 2003; 89:659-71.
2. Torsdottir G, Kristinsson J, SveinbjömsdotHr S, Snaedal
J, Johannesson T. Copper, ceruloplasmin, superoxide
dismutase and iron parameters in Parkinson's disease.
Pharmacol Toxicol 1999; 85:239-43.
3. Torsdottir G, Sveinbjömsdottir S, Kristinsson J, Snaedal J,
Johannesson T. Ceruloplasmin and superoxide dismutase
(SODl) in Parkinson's disease: A follow-up study. J Neurol
Sci 2006; 241: 53-8.
4. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir A,
Baldvinsson M, Johannesson T. Copper, cemloplasmin
and superoxide dismutase in patients with Alzheimer's
disease. A case-control study. Dement Geriatr Cogn Disord
1998; 9: 239-42. (Cp-sérvirkni í þessari rannsókn, sem
nefnd er í meginmáli, var fyrst reiknuð út síðar.)
5. Torsdottir G, Kristinsson J, Snaedal J, Johannesson T.
Cemloplasmin and iron proteins in the semm of patients
with Alzheimer's disease. Dement Geriatr Cogn Disord
Extra 2011; 1:366-71.
6. Holmberg CG, Laurell CB. Investigations in semm copper
I. Nature of semm copper and its relation to the iron-
binding protein in human semm. Acta Chem Scand 1947;
1:944-50.
7. Harris ZL, Morita H, Gitlin JD. The biology of human
cemloplasmin. In: Messerschmidt A, ed. Multi-Copper
Oxidases (chapter 10). World Scientific, Singapore 1997:
285-305.
8. Harris ZL, Takahashi Y, Miyajima H, Serizawa M,
MacGillivray RTA, Gitlin JD. Acemloplasminemia:
Molecular characterization of this disorder of iron
metabolism. Proc Natl Acad Sci 1995; 22: 2539-43.
9. Vassiliev V, Harris ZL, Zatta P. Cemloplasmin in
neurodegenerative diseases. Brain Res Rev 2005; 49: 633-
40.
10. Texel SJ, Xu X, Harris ZL. Cemloplasmin in
neurodegenerative diseases. Biochem Soc Trans 2008; 36:
1277-81.
11. Barber EF, Cousins RJ. Interleukin-l-stimulated induction
of cemloplasmin synthesis in normal and copper-deficient
rats. J Nutr 1988; 118:375-81.
12. Barber EF, Cousins RJ. Induction of cemloplasmin
synthesis by retinoic acid in rats: Influence of dietary
copper and vitamin A status. J Nutr 1987; 117:1615-22.
13. Roberts EA, Sarkar B. Liver as a key organ in the supply,
storage, and excretion of copper. Am J Clin Nutr 2008; 88 (
suppl): 851S-854S.
14. Torsdottir G, Gudmundsson G, Kristinsson J, Snaedal J,
Johannesson T. Cemloplasmin and superoxide dismutase
(SODl) in heterozygotes for Wilson disease: A case control
study. Neuropsychiatr Dis Treat 2009; 5:55-9.
15. Patel BN, David S. A novel glycosylphosphatidylinositol-
anchored form of ceruloplasmin is expressed by
mammalian astrocytes. J Biol Chem 1997; 272: 20185-90.
16. Hellman NE, Gitlin JD. Cemloplasmin metabolism and
function. Ann Rev Nutr 2002; 22:439-58.
17. Harris ZL, Klomp LW, Gitlin JD. Aceruloplasminemia:
an inherited neurodegenerative disease with impairment
of iron homeostasis. Am J Clin Nutr 1998; 67 (Suppl):
972S-977S.
18. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene
dismption reveals an essential role for cemloplasmin in
cellular iron efflux. Proc Natl Acad Sci 1999; 96:10812-7.
19. Jeong SY, David S. Glycosylphosphatidylinositol-
anchored cemloplasmin is required for iron efflux from
cells in the central nervous system. J Biol Chem 2003; 278:
27144-8.
20. De Domenico I, Ward DM, di Patti MCB, Jeong SY, David
S, Musci G, Kaplan J. Ferroxidase activity is required for
the stability of cell surface ferroportin in cells expressing
GPI-cemloplasmin. EMBO J 2007; 26:2823-31.
21. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR.
Iron, brain ageing and neurodegenerative disorders. Nat
Rev Neurosci 2004; 5: 863-73.
22. Altamura S, Muckenthaler MU. Iron toxicity in diseases
of aging: Alzheimer's disease, Parkinson's disease and
atherosclerosis. J Alzheimer's Dis 2009; 16:879-95.
23. Bamham KJ, Masters CL, Bush AI. Neurodegenerative
diseases and oxidative stress. Nat Rev Dmg Discov 2004;
3:205-14.
24. Amal N, Cristalli IX), de Alaniz MJT, Marra CA. Clinical
utility of copper, cemloplasmin, and metallothionein
plasma determinations in human neurodegenerative
patients and their first-degree relatives. Brain Res 2010;
1319:118-30.
25. Bhamcha KJ, Friedman JK, Vincent AS, Ross ED. Lower
semm cemloplasmin levels correlate with younger age of
onset in Parkinson's disease. J Neurol 2008; 255:1957-62.
26. Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, et al.
Decreased semm cemloplasmin levels characteristically
aggravate nigral iron deposition in Parkinson's disease.
Brain 2011; 134: 50-8.
27. Martinez-Hemandez R, Montes S, Higuera-Calleja J,
Yescas P, Boll MC, Diaz-Ruiz A, et al. Plasma
cemloplasmin ferroxidase activity correlates with the
nigral sonographic area in Parkinson's disease patients: A
pilot study. Neurochem Res 2011; 36: 2111-5.
28. Berg D, Hochstrasser H, Schweitzer KJ, Riess O.
Disturbance of iron metabolism in Parkinson's disease -
ultrasonography as a biomarker. Neurotox Res 2006; 9:
1-13.
29. Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel
J, Csoti I, et al. Cemloplasmin gene variations and
substantia nigra hyperechogenicity in Parkinson disease.
Neurology 2004; 63:1912-7.
30. Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen
M, et al. Neuromelanin can protect against iron-mediated
oxidative damage in system modeling iron overload of
brain aging and Parkinson's disease. J Neurochem 2008;
106:1866-75.
31. Uversky VN. Neurotoxicant-induced animal models of
Parkinson's disease: understanding the role of rotenone,
maneb and paraquat in neurodegeneration. Cell Tissue
Res 2004; 318:225-41.
32. Inden M, Kitamura Y, Abe M, Tamaki A, Takata K,
Taniguchi T. Parkinsonian rotenone mouse model:
Reevaluation of long-term administration of rotenone in
C57BL/6 mice. Biol Pharm Bull 2011; 34:92-6.
33. Hineno A, Kaneko K, Yoshida K, Ikeda S. Ceruloplasmin
protects against rotenone-induced oxidative stress and
neurotoxicity. Neurochem Res 2011; 36:2127-35.
34. Blennow K. Alzheimers sykdom - patofysiologi.
Information frán Lakemedelsverket 2002; 7/8: 21-34.
35. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A
histochemical study of iron, transferrin, and ferritin in
Alzheimer's diseased brains. J Neurosci Res 1992; 31:
75-83.
36. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ.
Regional distribution of iron and iron-regulatory proteins
in the brain in aging and Alzheimer's disease. J Neurosci
Res 1992; 31:327-35.
37. Smith MA, Harris PLK, Sayre LM, Perry G. Iron
accumulation in Alzheimer disease is a source of redox-
generated free radicals. Proc Natl Acad Sci 1997; 94: 9866-
8.
38. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW, Cohen
ML, et al. Increased iron and free radical generation
in preclinical Alzheimer disease and mild cognitive
impairment. J Alzheimers Dis 2010; 19: 363-72.
39. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A,
Balraj EK, et al. Oxidative damage is the earliest event in
Alzheimer disease. J Neuropathol Exp Neurol 2001; 60:
759-67.
40. Torsdottir G, Kristinsson J, Snaedal J, Sveinbjömsdottir
S, Gudmundsson G, Hreidarsson S, et al. Case-control
studies on ceruloplasmin and superoxide dismutase
(SODl) in neurodegenerative diseases: A short review. J
Neurol Sci 2010; 299:51-4.
41. Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF,
Heckman SM, Dick R. Copper and ceruloplasmin
abnormalities in Alzheimer's disease. Am J Alzheimers
Dis Other Demen 2010; 25:490-7.
42. Bucossi S, Ventriglia M, Panetta V, Salustri C, Pasqualetti
P, Mariani S, et al. Copper in Alzheimer's disease: A meta-
analysis of serum, plasma, and cerebrospinal fluid studies.
J Alzheimers Dis 2011; 24:175-85.
43. Squitti R, Ghidoni R, Scrascia F, Benussi L, Panetta
V, Pasqualetti P, et al. Free copper distinguishes mild
cognitive impairment subjects from healthy elderly
individuals. J Alzheimers Dis 2011; 23: 239-48.
44. Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM.
Iron, zinc and copper in the Alzheimer's disease brain: A
quantitative meta-analysis. Some insight on the influence
of citation bias on scientific opinion. Prog Neurobiol 2011;
94:296-306.
45. Choi BS, Zheng W. Copper transport to the brain by the
blood-brain barrier and blood-CSF barrier. Brain Res 2009;
1248:14-21.
46. Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich
V, Lolacono N, et al. Altered systemic iron metabolism in
Parkinson's disease. Neurology 1997; 49: 714-7.
47. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert
JC, Carrasquillo MM, et al. Common variants at ABCA7,
MS4A6A/ MS4A4E, EPHAl, CD33 and CD2AP are
associated with Alzheimer's disease. Nat Genet 2011; 43:
429-36.
48. Sveinbjömsdottir S, Hicks AA, Jonsson T, Petursson H,
Gudmundsson G, Frigge, et al. Familial aggregation of
Parkinson's disease in Iceland. N Engl J Med 2000; 343:
1765-70.
49. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM,
Mitsumoto H, Chung W, et al. Induced pluripotent
stem cells generated from patients with ALS can be
differentiated into motor neurons. Science 2008; 321:1218-
21.
LÆKNAblaðið 2012/98 537